IPO Update: YimuFeng Bio's Hong Kong Listing Application Expires

Stock News

Aug 13

The listing application submitted by Shenzhen YimuFeng Biotechnology Co., Ltd. (referred to as YimuFeng Bio) for its initial public offering on the Hong Kong Stock Exchange has lapsed. The prospectus, filed on February 13, 2026, reached its six-month validity period on August 13, 2026, becoming invalid.

At the time of the filing, Huatai International served as the sole sponsor. According to the previously disclosed prospectus, YimuFeng Bio is a globally leading innovative cell therapy company.

The company's core product, IMC002, is a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate. This therapy is the second-fastest progressing solid tumor CAR-T cell therapy candidate globally in clinical development and is currently in a pivotal clinical stage (Phase III clinical trial).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1180204977"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180204977\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180204977?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 06:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180204977","market":"sg","top_or_hot":-1,"title":"IPO Update: YimuFeng Bio's Hong Kong Listing Application Expires","media":"Stock News","content":"<p>The listing application submitted by Shenzhen YimuFeng Biotechnology Co., Ltd. (referred to as YimuFeng Bio) for its initial public offering on the Hong Kong Stock Exchange has lapsed. The prospectus, filed on February 13, 2026, reached its six-month validity period on August 13, 2026, becoming invalid.<br><br>At the time of the filing, <b>Huatai International</b> served as the sole sponsor. According to the previously disclosed prospectus, YimuFeng Bio is a globally leading innovative cell therapy company.<br><br>The company's core product, <b>IMC002</b>, is a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate. This therapy is the second-fastest progressing solid tumor CAR-T cell therapy candidate globally in clinical development and is currently in a pivotal clinical stage (Phase III clinical trial).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IPO Update: YimuFeng Bio's Hong Kong Listing Application Expires</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIPO Update: YimuFeng Bio's Hong Kong Listing Application Expires\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-13 06:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The listing application submitted by Shenzhen YimuFeng Biotechnology Co., Ltd. (referred to as YimuFeng Bio) for its initial public offering on the Hong Kong Stock Exchange has lapsed. The prospectus, filed on February 13, 2026, reached its six-month validity period on August 13, 2026, becoming invalid.<br><br>At the time of the filing, <b>Huatai International</b> served as the sole sponsor. According to the previously disclosed prospectus, YimuFeng Bio is a globally leading innovative cell therapy company.<br><br>The company's core product, <b>IMC002</b>, is a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate. This therapy is the second-fastest progressing solid tumor CAR-T cell therapy candidate globally in clinical development and is currently in a pivotal clinical stage (Phase III clinical trial).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1180204977","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180204977","pubTimestamp":1786574260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The listing application submitted by Shenzhen YimuFeng Biotechnology Co., Ltd. (referred to as YimuFeng Bio) for its initial public offering on the Hong Kong Stock Exchange has lapsed. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","REDS":"RPM Republican Senate ETF","FRHC":"Euronext CAC Health Care","KCE":"SPDR KBW Capital Markets ETF","IPOS":"Renaissance International IPO ETF","BK4588":"碎股","KCAI":"KraneShares China Alpha Index ETF","BK4585":"ETF&股票定投概念","BK4127":"投资银行业与经纪业"},"translate_title":"IPO更新：益母丰生物香港上市申请到期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCE":1,"VXUS":1,"REDS":1,"FRHC":1,"KCAI":1,"IPOS":1},"content_text":"The listing application submitted by Shenzhen YimuFeng Biotechnology Co., Ltd. (referred to as YimuFeng Bio) for its initial public offering on the Hong Kong Stock Exchange has lapsed. The prospectus, filed on February 13, 2026, reached its six-month validity period on August 13, 2026, becoming invalid.At the time of the filing, Huatai International served as the sole sponsor. According to the previously disclosed prospectus, YimuFeng Bio is a globally leading innovative cell therapy company.The company's core product, IMC002, is a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate. This therapy is the second-fastest progressing solid tumor CAR-T cell therapy candidate globally in clinical development and is currently in a pivotal clinical stage (Phase III clinical trial).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}